ASX - By Stock
|
NC6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Quiltman
|
18 |
3.0K |
6 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
18
|
3.0K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Quiltman
|
42 |
9.6K |
41 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
42
|
9.6K
|
41
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Quiltman
|
227 |
50K |
25 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
227
|
50K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
9 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
1.3K
|
331K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
13 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
1.3K
|
331K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
8 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
1.3K
|
331K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
17 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.3K
|
331K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Quiltman
|
104 |
18K |
9 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
18K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Quiltman
|
104 |
18K |
18 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
104
|
18K
|
18
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Quiltman
|
18 |
3.0K |
2 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
18
|
3.0K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
21 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
24 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
261
|
66K
|
24
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
16 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
261
|
66K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
13 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
66K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
25 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
66K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
17 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
66K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Quiltman
|
261 |
66K |
21 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
66K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
23 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
20 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
28 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
Quiltman
|
37 |
8.9K |
29 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
8.9K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
19 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
20 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
36 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
36 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
Quiltman
|
100 |
26K |
9 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
100
|
26K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
20 |
14/04/24 |
14/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
90 |
21K |
15 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
90
|
21K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
23 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
18 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
20 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
17 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
47 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
47
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
90 |
21K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
90
|
21K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Quiltman
|
77 |
19K |
23 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Quiltman
|
77 |
19K |
31 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
31
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
90 |
21K |
13 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
90
|
21K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Quiltman
|
77 |
19K |
26 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
26
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
90 |
21K |
13 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
90
|
21K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
25 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
11 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Quiltman
|
1.3K |
331K |
24 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.3K
|
331K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Quiltman
|
66 |
18K |
28 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Quiltman
|
66 |
18K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Quiltman
|
66 |
18K |
18 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
18
|
|